

Interferon- γ down-regulates expression of tumor necrosis factor- α converting enzyme/a disintegrin and metalloproteinase 17 in activated hepatic stellate cells of rats

TOMOHIRO FUJITA^{1,2}, CHIHAYA MAESAWA¹, KANTA OIKAWA¹,
HIROYUKI NITTA², GO WAKABAYASHI² and TOMOYUKI MASUDA¹

Departments of ¹Pathology and ²Surgery I, Iwate Medical University School of Medicine, Morioka 020-8505, Japan

Received November 25, 2005; Accepted January 3, 2006

Abstract. Interferon- γ (IFN- γ) is a potent cytokine that exerts antiproliferative and antifibrogenic effects on hepatic stellate cells (HSCs). Although therapeutic application of IFN- γ for chronic liver diseases is anticipated, the responses of activated HSCs to IFN- γ have not been fully elucidated. To seek unknown molecules and pathways that might be responsive to IFN- γ treatment in activated HSCs, we examined global protein expression profiles using two-dimensional gel electrophoresis combined with peptide mass fingerprint. We identified 76 increased and 59 decreased spots (>3-fold increase or decrease, total 135 spots). Database analysis suggested that the following four pathways were involved in alteration of HSCs toward a quiescent phenotype in response to IFN- γ : i) down-regulation of the TGF- β and PDGF signaling pathways; ii) reorganization of intermediate filaments; iii) up-regulation of fatty acid metabolism; iv) decreased expression of TNF- α converting enzyme (TACE)/a disintegrin and metalloproteinase 17 (ADAM17), which is responsible for shedding of the pro-inflammatory cytokine TNF- α . We confirmed down-regulation of both ADAM17 expression and soluble TNF- α secretion by Western blotting and real-time PCR. TNF- α mRNA/protein expression was not altered by IFN- γ treatment. Our data suggest that IFN- γ stimulation suppresses the activated phenotype of HSCs *in vitro* through multiple pathways. Of these pathways, down-regulation of ADAM17 expression may play a role in blocking the auto-activation mechanism of cultured HSCs through activation of the TNF- α signaling and shedding pathways.

Introduction

Liver fibrosis is the common sequel of chronic liver injury regardless of its etiology (viral infection, metabolic disease or toxins). Many studies have suggested that hepatic stellate cells (HSCs) play a pivotal role in the initiation and/or progression of liver fibrosis (1-12). In normal liver, HSCs are the site of storage and metabolism of vitamin A (6,7). Following chronic liver injury, HSCs undergo a process of activation, developing a myofibroblast-like appearance (1-12). Activated HSCs appear to lose their lipid droplets, increase their rough endoplasmic reticulum, express α -smooth muscle actin (α -SMA), and increase their synthesis of extracellular matrix components and fibrosis-implementing factors, such as transforming growth factor- β 1 (TGF- β 1) and platelet-derived growth factor receptor- β (PDGFR- β) (1-12). Therefore, it is not surprising that activated HSCs are considered a major cellular target for the treatment of liver fibrosis.

Interferon- γ (IFN- γ) is a potent cytokine that exerts immunomodulatory and antiproliferative effects on certain mesenchymal cells. It has also been shown to have antifibrogenic effects on cultured fibroblasts (13-16), chondrocytes (17), cultured fetal bone (18) and vascular myofibroblasts (19). *In vivo* experiments have shown that locally or systemically administered recombinant murine IFN- γ reduces the collagen content of skin wounds in mice (20). IFN- γ also exerts antiproliferative and antifibrogenic effects on cultured HSCs (21). Moreover, IFN- γ -deficient mice exhibit an increased susceptibility to hepatic fibrosis after injury (22). Although therapeutic applications of IFN- γ for chronic liver diseases are anticipated, the responses of activated HSCs to IFN- γ have not been fully elucidated.

To seek unknown molecules that might be responsive to IFN- γ treatment in activated HSCs, we examined global protein expression profiles using two-dimensional gel electrophoresis (2-DE) combined with peptide mass fingerprint (PMF)/post-source decay (PSD).

Materials and methods

Isolation of HSCs and culture conditions. HSCs were isolated and enriched using a modification of the method of Senoo (23). All rats were treated according to the Japanese National

Correspondence to: Dr Chihaya Maesawa, Department of Pathology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka 020-8505, Japan
E-mail: chiahaya@iwate-med.ac.jp

Key words: hepatic stellate cells, interferon- γ , tumor necrosis factor- α , ADAM17, proteome

Guidelines for the Care of Animals. HSCs were isolated from male Wistar rats, weighing 250–300 g, by using collagenase digestion followed by density gradient centrifugation. After isolation, the cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Invitrogen). HSCs were incubated at 37°C in a humidified atmosphere with 5% CO₂, and the medium was changed twice a week. When the cells became confluent, they were trypsinized and replated on plastic culture dishes at a density of 1×10⁶ cells/cm². Experiments were performed using cells after 3 passages from the primary culture for *in vitro* activation of HSCs.

IFN- γ treatment. Treatment with recombinant rat interferon- γ (IFN- γ ; BioSource International Camarillo, CA, USA) was performed according to standard procedures to investigate the possible antifibrogenic effect of the compound, as described previously (24). Briefly, HSCs were plated and grown for 7 days until subconfluency. Subsequently, they were washed 5 times with serum-free DMEM. IFN- γ was added to a final concentration of 1×10³ U/ml in DMEM supplemented with 0.3% FBS (24). After treatment with IFN- γ for 6, 12 and 48 h, mRNA and/or protein were extracted.

Preparation of cellular protein. The HSCs were harvested and washed 3 times with ice-cold Dulbecco's phosphate-buffered saline (PBS, Invitrogen). They were then dissolved in lysis buffer consisting of 7 M urea, 2 M thiourea, 4% (wt/vol) 3-3-cholamidopropyltrimethylammonio-1-propanesulfonate, 1% dithiothreitol (DTT), and 0.5% (vol/vol) IPG buffer (pH 4.0–7.0 and/or pH 3.0–10; Amersham Biosciences, Piscataway, NJ, USA). All samples were incubated for 1 h at room temperature, and then centrifuged for 1 h at 40,000 g to remove DNA. The protein concentration of each sample was measured using a Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA), a microplate reader (Vmax, Molecular Devices, Sunnyvale, CA, USA) and SOFTmax PRO software (Molecular Devices).

Two-dimensional electrophoresis (2-DE). Using 300 μ g of cellular protein extracted from HSCs, isoelectric focusing (IEF) was carried out with Immobiline DryStrips (linear pH gradient 4.0–7.0, 18 cm, non-linear pH gradient of 3–10, 24 cm; Amersham Biosciences). The gels were rehydrated for 12–15 h by placing the strips gel side down in an Immobiline DryStrip Reswelling Tray (Amersham Biosciences), with rehydration solution covered by DryStrip Cover Fluid (Amersham Biosciences). IEF was carried out using an Ettan™ IPGphor™ (Amersham Biosciences) at 20°C. The first phase was set at 500 V for 1 min, and the second phase at 4,000 V for 1.5 h. Both phases were a linear gradient spanning for each time. The final phase was set at 8,000 V for 3–10 h. Prior to second-dimensional electrophoresis, the IPG gel strips were incubated at room temperature for 15 min in an equilibration solution (50 mM Tris-HCl/pH 8.8, 6 M urea, 2% SDS, 30% glycerol, trace bromophenol blue and 1% DTT). This was followed by incubation for 15 min in the equilibration solution containing 2.5% iodoacetamide. The gels were subsequently subject to a second-dimensional run using an Ettan™ DALT Six Large Electrophoresis Unit (Amersham Biosciences) at 4°C on Ettan

DALT Gel (12.5%, 26×20 cm, Amersham Biosciences). The first phase was set at 2.5 W/gel for 30 min. The second phase was set at 100 W for 3.5–5 h until the bromophenol blue reached the bottom of the gel. The 2-DE gels were finally stained with a Silver Staining Kit, Protein (Amersham Biosciences).

Gel analysis. The silver-stained 2-DE gels were scanned on an Epson ES 2200 scanner (Seiko Epson Corp., Suwa, Japan) and the images were processed using Adobe Photoshop software (version 5.0, San Jose, CA, USA). Spot detection and matching were performed using the PDQuest version 7.2 software package (Bio-Rad). Protein spots were checked manually to eliminate artifacts due to gel distortion, abnormal silver staining or poorly detectable spots. Protein level of each spot with an increased or decreased 3-fold over the untreated controls after treatment with IFN- γ was considered to show a substantial change. We used a 'Total Quantity in Valid Spots' method as the normalization method.

In-gel digestion. Spots of interest were manually excised from 2-DE gels and transferred to a ZipPlate micro-SPE plate (Millipore, Bedford, MA, USA). The procedure employed was essentially as described previously (25,26) with slight modifications.

Matrix-assisted laser desorption/ionization time of flight mass spectrometry analysis. Mass information on the peptides was obtained using a MALDI-TOF (matrix-assisted laser desorption/ionization time of flight) mass spectrometer (Voyager™ DE-STR, Applied Biosystems, Foster City, CA, USA) according to a previously published protocol. The peptide mixture (1 μ l) was crystallized with an equivalent volume of freshly prepared α -cyano-4-hydroxycinnamic acid matrix solution (10 mg/ml; Sigma Chemical Co., St. Louis, MO, USA) in 50% acetonitrile (Sigma)/0.1% trifluoroacetic acid (Kanto Chemical, Tokyo, Japan) onto the MALDI target plate. TOF spectra were acquired over the m/z range of 700–3,000 Da in the delayed extraction and reflector mode. External calibration was performed using Angiotensin I (M⁺H⁺, 1,296.70 Da), ACTH (clip 1–17 M⁺H⁺, 2,093.08 Da), ACTH (clip 18–39 M⁺H⁺, 2,465.20 Da) and ACTH (clip 7–38 M⁺H⁺, 3,657.93 Da) in the same series as the samples to be measured. Internal calibration was also performed using auto-digestion peaks of trypsin (M⁺H⁺, 842.51 and 2,211.10 Da). TOF spectra were acquired over the m/z range of 700–3,000 Da in the delayed extraction and reflector mode.

Initially, the samples were subjected to peptide mass fingerprint (PMF) analysis. The resulting peptide masses were then searched against the SWISS-PROT and NCBI non-redundant databases using the MS-fit software package (<http://prospector.ucsf.edu/ucsfhtml14.0/msfit.htm>; Protein Prospector, UCSF, San Francisco, CA, USA). The MS-fit search was performed with the following parameters: all molecular weight ranges, all pH ranges, oxidation of methionine, acetylation of the N-terminus, carboxyamidomethylation of cysteine, and phosphorylation of serine, threonine and tyrosine. Positive identification of a protein was assigned only if at least five peptide masses matched a particular hit in the database within a mass tolerance of 50 ppm or lower, matched peptide




Figure 1. Two-DE pattern of proteins extracted from HSCs without (A) and with (B) IFN- γ treatment for 48 h. The proteins (300 μ g) were separated by 2-DE (IPG gel strip, 18 cm, pH 4.0-7.0) and the proteins in the second-dimension gel were silver-stained. Representative numbers are identical to those in Tables I and II. Fifty-nine decreased and 76 increased spots were indicated in gels A and B, respectively.

masses were evenly distributed throughout its amino acid sequence, and the identified protein's molecular weight and pH approximated experimental values, with some exceptions. Protein spots that could not be matched convincingly with any database hit, or spots that contained unidentified peaks, were further subjected to post-source decay (PSD) analysis. The resulting peptide masses were then searched against the SWISS-PROT and NCBI non-redundant databases using the MS-Tag software package (<http://prospector.ucsf.edu/ucsfhtm14.0/mstagfd.htm>; Protein Prospector). Positive protein identification was confirmed by comparing its theoretical tryptic peptide digests with MALDI spectra, obtaining additional sequence information from another peptide, and using the Mascot Program (<http://www.matrixscience.com/>) to reconfirm the hit.

RNA extraction and real-time quantitative PCR. Total RNA was extracted with an RNeasy Mini Kit (Qiagen Sciences, Valencia, CA, USA) according to the manufacturer's protocol, and cDNA was synthesized with a ThermoScript RT-PCR Kit (Invitrogen) and oligo-dT primer. We performed the real-time quantitative PCR assay with an ABI PRISM 7700 Sequence Detector (Applied Biosystems). Primers were designed with Primer Express software (Applied Biosystems). The reaction mixture contained 50 ng of cDNA, 100 nmol/l each primer, and 25 μ l of SYBR Green PCR Master Mix (Applied Biosystems) in a final volume of 50 μ l. The cDNA was subjected to 50 cycles of a two-step PCR consisting of 15 sec denaturation at 95°C and 1 min combined annealing/extension at 60°C. Each sample was run in triplicate in separate tubes. For normalization of each target in the samples, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used

as an internal control (Applied Biosystems). Primer sequences for tumor necrosis factor (TNF)- α converting enzyme (TACE)/a disintegrin and metalloproteinase 17 (ADAM17) were ADAM17-F-GTG CTG ACA CCG ACA ACT CGT and ADAM17-R-CAG CTG GTC AAT GAA ATC CCA, and those of tumor necrosis factor (TNF)- α were TNF- α -F-CAG CCG GTT TGC CAT TTC AT and TNF- α -R-GGT GTC CTT AGG GCA AGG GC. All data were calculated by the comparative Ct method (27) to detect fold changes in mRNA expression.

Western blot analysis. We examined several proteins by Western blot analysis. The primary antibodies used were monoclonal α -SMA (1:1,000; Sigma), polyclonal anti-PDGFR- β (Clone 958, 1:1,000; Santa Cruz, CA, USA), polyclonal anti-TGF- β 1 (sc-146, 1:500; Santa Cruz), polyclonal anti-ADAM-17 (1:1,000; Sigma), monoclonal anti-tumor necrosis factor- α (1:1,000; Sigma), and monoclonal anti- β -actin (1:1,000; Sigma). The secondary antibody, anti-mouse IgG or anti-rabbit IgG (Amersham Biosciences), was diluted 1:10,000 in blocking buffer. Immunoreactive bands were visualized with an ECL Plus System (Amersham Biosciences).

Cytokine assay. To evaluate the increase of TNF- α secretion in the supernatant of HSC cultures, we employed a LabMAP (Multi-Analyte Profiling) system, which is based on antibody-coupled microspheres and flow cytometer assay, and has been used for quantifying multiple cytokines in several biological fluids including human serum. The method is feasible and cost-effective for cytokine profiling. We used a Bio-Plex™ RAT Cytokine 8-Plex Panel (Bio-Rad Laboratories, Inc.) and a Bio-Plex Suspension Array System (Bio-Rad). The limits

Table I. Proteins showing down-regulation in activated hepatic stellate cells after treatment with IFN- γ for 48 h, detected by two-dimensional gel electrophoresis combined with peptide mass fingerprint/post-source decay.

| No. | Swiss-Plot Accession no. | Pep | M | Fold change | Gene symbol | Protein name |
|----------------------------|-----------------------------|-----|----|----------------|-------------------|---|
| Binding | | | | | | |
| 1 | P25977 | 6 | 71 | -11.3 | Acta2 | Nucleolar transcription factor 1 |
| 2 | Q99PK0 | 10 | 99 | -7.7 | Xab2 | XPA-binding protein 2 |
| 3 | Q9Z1K9 | 5 | 93 | -7.4 | Adam17 | ADAM 17 |
| 4 | Q9QY02 | 6 | 85 | -4.8 | Yt521 | Putative splicing factor YT521 |
| 5 | Q9R011 | 5 | 68 | -4.6 | Plk3 | Serine/threonine-protein kinase PLK3 |
| 6 | Q63202 | 5 | 82 | -3.9 | Adam2 | ADAM 2 |
| 7 | P97834 | 8 | 53 | -3.9 | Gps1 | COP9 signalosome complex subunit 1 |
| 8 | Q9ESM2 | 5 | 38 | -3.9 | Hapln2 | Hyaluronan and proteoglycan link protein 2 |
| 9 | P55063 | 10 | 70 | -3.6 | Hspa11 | Heat shock 70 kDa protein 1L |
| 10 | P04276 | 8 | 53 | -3.6 | Gc | Vitamin D-binding protein |
| 11 | Q99P74 | 5 | 24 | -3.5 | Rab27b | Ras-related protein Rab-27B |
| 12 | P06761 | 6 | 72 | -3.2 | Hspa5 | 78-kDa glucose-regulated protein |
| 13 | P97779 | 13 | 57 | -3.1 | Hmmr | Hyaluronan mediated motility receptor |
| 14 | P13596 | 7 | 94 | -3.1 | Ncam1 | Neural cell adhesion molecule 1140 kDa isoform |
| 15 | Q64725 | 5 | 71 | -3.1 | Syk | Tyrosine-protein kinase SYK |
| Catalytic activity | | | | | | |
| 16 | P19637 | 10 | 62 | -13.2 | Plat | Tissue-type plasminogen activator |
| 17 | Q60587 | 6 | 51 | -10.3 | Hadhb | Trifunctional enzyme β -subunit, mitochondrial |
| 18 | Q64595 | 7 | 87 | -7.3 | Prkg2 | cGMP-dependent protein kinase 2 |
| 19 | P19468 | 7 | 72 | -6.8 | Gclc | Glutamate-cysteine ligase catalytic subunit |
| 20 | Q9EQS0 | 5 | 37 | -5.9 | Taldo1 | Transaldolase |
| 21 | Q64637 | 9 | 60 | -5.8 | Ugt1 | UDP-glucuronosyltransferase 1-3 precursor, microsomal |
| 22 | P06536 | 5 | 87 | -5.7 | Nr3c1 | Glucocorticoid receptor |
| 23 | P13195 | 6 | 71 | -4.2 | Alas1 | 5-aminolevulinate synthase, non-specific, mitochondrial |
| 24 | P14646 | 5 | 82 | -4.1 | Pde4b | cAMP-specific 3',5'-cyclic phosphodiesterase 4B |
| 25 | P18589 | 6 | 75 | -3.9 | Mx2 | Interferon-induced GTP-binding protein Mx2 |
| 26 | P35571 | 7 | 80 | -3.6 | Gpd2 | Glycerol-3-phosphate dehydrogenase, mitochondrial |
| 27 | P20069 | 5 | 58 | -3.6 | Pmpca | Mitochondrial processing peptidase α subunit, mitochondrial |
| 28 | P09811 | 8 | 97 | -3.5 | Pygl | Glycogen phosphorylase, liver form |
| 29 | Q8R4C0 | 8 | 73 | -3.4 | Capn5 | Calpain 5 |
| 30 | Q63108 | 5 | 61 | -3.4 | Ces1 | Liver carboxylesterase 3 |
| 31 | P35704 | 5 | 21 | -3.4 | Prdx2 | Peroxiredoxin 2 |
| 32 | P28841 | 5 | 70 | -3.2 | Pcsk2 | Neuroendocrine convertase 2 |
| 33 | O88496 | 5 | 87 | -3.2 | Ggcs | Vitamin K-dependent gamma-carboxylase |
| 34 | P07153 | 5 | 68 | -3.1 | Rpn1 | Dolichyl-diphosphooligosaccharide-protein glycosyl-transferase 67-kDa subunit |
| 35 | P50282 | 6 | 78 | -3.1 | Mmp9 | Matrix metalloproteinase-9 |
| 36 | Q9ES66 | 6 | 74 | -3.0 | Capn10 | Calpain 10 |
| 37 | O35776 | 5 | 63 | -3.0 | Has2 | Hyaluronan synthase 2 |
| 38 | Q64573 | 10 | 62 | -3.0 | Ces1 ^a | Liver carboxylesterase 4 |
| Signal transducer activity | | | | | | |
| 39 | Q04589 | 5 | 91 | -6.0 | Fgfr1 | Basic fibroblast growth factor receptor 1 |

Table I. Continued.

| No. | Swiss-Plot Accession no. | Pep | M | Fold change | Gene symbol | Protein name |
|---|-----------------------------|-----|----|----------------|----------------|--|
| Signal transducer activity | | | | | | |
| 40 | Q05030 | 6 | 56 | -5.5 | Pdgfrb | β platelet-derived growth factor receptor |
| 41 | P80204 | 5 | 56 | -4.1 | Tgfbr1 | TGF- β receptor type I |
| 42 | Q9R237 | 7 | 77 | -3.7 | Mapk8ip1 | c-jun-amino-terminal kinase interacting protein 1 |
| 43 | O08876 | 8 | 51 | -3.6 | Klf10 | Transforming growth factor- β -inducible early growth response protein 1 |
| 44 | P42893 | 11 | 86 | -3.3 | Ece1 | Endothelin-converting enzyme 1 |
| 45 | P17246 | 6 | 44 | -3.0 | Tgfb1 | Transforming growth factor- β 1 |
| Structural molecule activity | | | | | | |
| 46 | Q05764 | 13 | 80 | -9.9 | Add2 | β adducin |
| 47 | P31000 | 5 | 53 | -7.1 | Vim | Vimentin |
| 48 | P04691 | 8 | 49 | -4.2 | Tubb | Tubulin β chain |
| 49 | P62738 | 14 | 42 | -3.3 | Acta2 | Actin, aortic smooth muscle |
| 50 | P47819 | 7 | 49 | -3.0 | Gfap | Glial fibrillary acidic protein, astrocyte |
| Transcription regulator activity | | | | | | |
| 51 | Q9JIL3 | 6 | 97 | -9.4 | Ilf3 | Interleukin enhancer-binding factor 3 |
| Transporter activity | | | | | | |
| 52 | O88943 | 9 | 93 | -4.6 | Kcnq2 | Potassium voltage-gated channel subfamily KQT member 2 |
| 53 | P10499 | 5 | 56 | -3.0 | Kcna1 | Potassium voltage-gated channel subfamily A member 1 |
| Others | | | | | | |
| 54 | P06399 | 5 | 86 | -10.3 | Fga | Fibrinogen α/α -E chain |
| 55 | Q63083 | 6 | 53 | -9.3 | Nucb1 | Nucleobindin 1 |
| 56 | Q99PV3 | 10 | 84 | -4.1 | Mkln1 | Muskelin |
| 57 | P43884 | 5 | 55 | -4.1 | Plin | Perilipin |
| 58 | Q02435 | 7 | 68 | -3.4 | Bfsp1 | Filensin |
| 59 | P14480 | 6 | 54 | -3.0 | Fgb | Fibrinogen β chain |

No., number (numbers are identical to those of Fig. 1); Pep, peptide; M, molecular mass; ^ainterim symbol.

of target detection were 2-32,000 pg/ml. The assays were performed according to the manufacturer's instructions. Triplicate examinations were performed on each sample.

Results

Two-DE followed by PMF/PSD analysis. 2-DE gel separation was carried out to find proteins that were influenced by IFN- γ . After spot detection, background subtraction and volume normalization, 722 \pm 17.8 and 747 \pm 21.1 spots were seen in gels with and without IFN- γ treatment, respectively (Fig. 1). We identified 123 increased and 64 decreased spots. Using PMF/PSD analysis, we were finally able to determine 76 increased and 59 decreased spots (Tables I and II, Fig. 1; Nos.

in Fig. 1 are identical to those in Tables I and II). Functions of these proteins were annotated according to the Rat Genome Database (RDG; <http://rgd.mcw.edu/>, October 2005), and over-represented gene groups with molecular functions (Gene Ontology, GO; <http://www.geneontology.org/>) (Tables I and II, Fig. 2). The number of proteins did not essentially differ between up- and down-regulated proteins in each molecular function category (Fig. 2).

Differential protein expression associated with an activated phenotype of HSCs under the influence of IFN- γ . Table III summarizes our data for markers of the activated phenotype of HSCs, myofibroblast-like cells, and activated fibroblasts.

Table II. Proteins showing up-regulation in activated hepatic stellate cells after treatment with IFN- γ for 48 h, detected by two-dimensional gel electrophoresis combined with peptide mass fingerprint/post-source decay.

| No. | Swiss-Plot Accession no. | Pep | M | Fold change | Gene symbol | Protein name |
|---------|-----------------------------|-----|----|----------------|----------------|--|
| Binding | | | | | | |
| 60 | Q9EPY0 | 7 | 62 | 91.7 | Card9 | Caspase recruitment domain protein 9 |
| 61 | P51792 | 5 | 84 | 17.8 | Clcn3 | Chloride channel protein 3 |
| 62 | Q62929 | 8 | 64 | 5.9 | Il1rl2 | Interleukin-1 receptor-like 2 |
| 63 | Q9Z2S9 | 6 | 47 | 5.6 | Flot2 | Flotillin-2 |
| 64 | P48679 | 5 | 74 | 5.4 | Lmna | Lamin A |
| 65 | O70418 | 6 | 68 | 5.2 | Znf179 | Zinc finger protein 179 |
| 66 | P70531 | 7 | 81 | 4.7 | Eef2k | Elongation factor 2 kinase |
| 67 | O88884 | 5 | 91 | 4.5 | Akap1 | A kinase anchor protein 1, mitochondrial |
| 68 | P16446 | 8 | 31 | 4.3 | Pitpna | Phosphatidylinositol transfer protein α isoform |
| 69 | P48037 | 5 | 75 | 3.6 | Anxa6 | Annexin A6 |
| 70 | Q62698 | 8 | 54 | 3.6 | Dncli2 | Dynein light intermediate chain 2, cytosolic |
| 71 | O54835 | 6 | 48 | 3.6 | Smad9/8 | Mothers against decapentaplegic homolog 9 |
| 72 | Q63598 | 5 | 70 | 3.5 | Pls3 | T-plastin |
| 73 | Q63570 | 6 | 47 | 3.4 | Psmc4 | 26S protease regulatory subunit 6B |
| 74 | O88797 | 6 | 82 | 3.3 | Dab2 | Disabled homolog 2 |
| 75 | P35565 | 8 | 67 | 3.2 | Canx | Calnexin |
| 76 | P35444 | 7 | 82 | 3.2 | Comp | Cartilage oligomeric matrix protein |
| 77 | P14668 | 5 | 35 | 3.1 | Anxa5 | Annexin A5 |
| 78 | Q924K2 | 6 | 73 | 3.1 | Faf1 | FAS-associated factor 1 |
| 79 | Q62918 | 5 | 90 | 3.1 | Nell2 | Protein kinase C-binding protein NELL2 |
| 80 | P20717 | 7 | 75 | 3.1 | Padi2 | Protein-arginine deiminase type II |
| 81 | Q9JKT5 | 6 | 35 | 3.1 | Tas2r9 | Taste receptor type 2 member 9 |
| 82 | P20417 | 5 | 49 | 17.8 | Ptpn1 | Tyrosine-protein phosphatase, non-receptor type 1 |
| 83 | P47942 | 5 | 62 | 11.6 | Dpysl2 | Dihydropyrimidinase related protein-2 |
| 84 | Q9QZ86 | 6 | 60 | 11.3 | Nop5 | Nucleolar protein NOP5 |
| 85 | O54697 | 5 | 80 | 8.9 | Naaladl1 | N-acetylated- α -linked acidic dipeptidase like protein |
| 86 | P20793 | 5 | 69 | 5.0 | Mak | Serine/threonine-protein kinase MAK |
| 87 | P97679 | 6 | 84 | 4.5 | Mlh1 | DNA mismatch repair protein Mlh1 |
| 88 | P51639 | 5 | 96 | 4.2 | Hmgcr | 3-hydroxy-3-methylglutaryl-coenzyme A reductase |
| 89 | P32738 | 5 | 71 | 4.1 | Chat | Choline O-acetyltransferase |
| 90 | P22791 | 5 | 56 | 4.0 | Hmgcs2 | Hydroxymethylglutaryl-CoA synthase, mitochondrial |
| 91 | P09812 | 5 | 97 | 3.9 | Pygm | Glycogen phosphorylase, muscle form |
| 92 | P53042 | 5 | 56 | 3.9 | Ppp5c | Serine/threonine protein phosphatase 5 |
| 93 | P53669 | 5 | 72 | 3.8 | Limk1 | LIM domain kinase 1 |
| 94 | P41562 | 7 | 46 | 3.7 | Idh1 | Isocitrate dehydrogenase (NADP) cytoplasmic |
| 95 | Q9QX05 | 8 | 96 | 3.6 | Tlr4 | Toll-like receptor 4 |
| 96 | P14882 | 5 | 77 | 3.6 | Pcca | Propionyl-CoA carboxylase α chain, mitochondrial |
| 97 | P51590 | 5 | 57 | 3.6 | Cyp2j3 | Cytochrome P450 2J3 |
| 98 | P10760 | 5 | 47 | 3.6 | Ahcy | Adenosylhomocysteinase |
| 99 | P29418 | 5 | 57 | 3.5 | Atp5e | ATP synthase epsilon chain, mitochondrial |
| 100 | P21575 | 8 | 95 | 3.4 | Dnm1 | Dynamin-1 |
| 101 | O54735 | 7 | 94 | 3.4 | Pde5a | cGMP-specific 3',5'-cyclic phosphodiesterase |
| 102 | Q63151 | 11 | 80 | 3.4 | Acs13 | Long-chain-fatty-acid-CoA ligase 3 |
| 103 | P07896 | 5 | 78 | 3.4 | hadh | Peroxisomal bifunctional enzyme |

Table II. Continued.

| No. | Swiss-Plot Accession no. | Pep | M | Fold change | Gene symbol | Protein name |
|----------------------------------|-----------------------------|-----|----|----------------|----------------|--|
| Catalytic activity | | | | | | |
| 104 | O35547 | 5 | 74 | 3.3 | Acs14 | Long-chain-fatty-acid-CoA ligase 4 |
| 105 | P22443 | 5 | 58 | 3.3 | Cyp19a1 | Cytochrome P450 19A1 |
| 106 | Q99JD2 | 7 | 48 | 3.3 | Tekt1 | Tektin-1 |
| 107 | P06766 | 5 | 38 | 3.3 | Polb | DNA polymerase β |
| 108 | P31325 | 8 | 46 | 3.2 | Phkg2 | Phosphorylase B kinase gamma catalytic chain, testis/liver isoform |
| 109 | Q08877 | 9 | 95 | 3.1 | Dnm3 | Dynamin 3 |
| 110 | P97564 | 5 | 93 | 3.1 | Gpam | Glycerol-3-phosphate acyltransferase, mitochondrial |
| 111 | O55096 | 5 | 83 | 3.1 | Dpp3 | Dipeptidyl-peptidase III |
| 112 | P97524 | 8 | 70 | 3.1 | Slc27a2 | Very-long-chain acyl-CoA synthetase |
| 113 | P15129 | 5 | 58 | 3.1 | Cyp4b1 | Cytochrome P450 4B1 |
| 114 | P33124 | 8 | 78 | 3.0 | Acs16 | Long-chain-fatty-acid-CoA ligase 6 |
| 115 | Q63802 | 6 | 71 | 3.0 | Wee1 | Wee1-like protein kinase |
| 116 | P04642 | 6 | 36 | 3.0 | Ldha | L-lactate dehydrogenase A chain |
| Signal transducer activity | | | | | | |
| 117 | P31421 | 7 | 95 | 4.4 | Grm2 | Metabotropic glutamate receptor 2 |
| 118 | P49805 | 7 | 77 | 4.1 | Rgs9 | Regulator of G-protein signaling 9 |
| 119 | P31422 | 6 | 98 | 3.9 | Grm3 | Metabotropic glutamate receptor 3 |
| 120 | P37230 | 5 | 52 | 3.4 | Ppara | Peroxisome proliferator activated receptor α |
| 121 | P97636 | 6 | 22 | 3.3 | Il18 | Interleukin-18 |
| 122 | P17945 | 6 | 82 | 3.1 | Hgf | Hepatocyte growth factor |
| Structural molecule activity | | | | | | |
| 123 | P48675 | 6 | 53 | 3.9 | Des | Desmin |
| Transcription regulator activity | | | | | | |
| 124 | P43301 | 5 | 42 | 4.0 | Egr3 | Early growth response protein 3 |
| Enzyme regulator activity | | | | | | |
| 125 | Q9Z272 | 5 | 85 | 3.9 | Git1 | ARF GTPase-activating protein GIT1 |
| 126 | P05710 | 5 | 68 | 3.7 | Prlr | Prolactin receptor |
| 127 | P37727 | 5 | 72 | 3.6 | Chm | Rab proteins geranylgeranyltransferase component A 1 |
| Others | | | | | | |
| 128 | P48998 | 7 | 67 | 5.5 | Ivl | Involucrin |
| 129 | P12839 | 8 | 95 | 3.6 | Nef3 | Neurofilament triplet M protein |
| 130 | P97675 | 5 | 99 | 3.4 | Ennp3 | Ectonucleotide pyrophosphatase/phosphodiesterase 3 |
| 131 | Q9QZ81 | 6 | 97 | 3.4 | Eif2c2 | Eukaryotic translation initiation factor 2C 2 |
| 132 | Q64548 | 5 | 83 | 3.4 | Rtn1 | Reticulon 1 |
| 133 | O55197 | 5 | 52 | 3.1 | C3ar1 | C3a anaphylatoxin chemotactic receptor |
| 134 | Q62774 | 7 | 97 | 3.1 | Myo1a | Myosin Ia |
| 135 | P57790 | 6 | 69 | 3.0 | Keap1 | Kelch-like ECH-associated protein 1 |

No., number (numbers are identical to those of Fig. 1); Pep, peptide; M, molecular mass.




Figure 2. Histograms of proteins altered by IFN- γ treatment. Protein annotation corresponds to molecular function (Gene Ontology, GO; <http://www.geneontology.org/>).

We found that IFN- γ treatment resulted in down-regulation of structural molecules, α -SMA (Acta2), vimentin (Vim), and glial fibrillary acidic protein (Gfap), which are conspicuous marker proteins that are up-regulated in activated HSCs, myofibroblast-like cells and/or activated fibroblasts (Table III). The expression of desmin (Des), which is also an activated marker for these cell types, was also up-regulated by IFN- γ . Both tubulin β chain (Tubb) and beta adductin (Add2), whose relationship to HSC activation has not yet been fully described, were down-regulated by IFN- γ treatment.

Among cytokines, growth factors and their receptors, three well-described fibrosis-implementing factors, β platelet-derived growth factor receptor (Pdgfrb), transforming growth factor- β 1 (Tgfb1), and TGF- β type I receptor (Tgfr1), were down-regulated upon treatment with IFN- γ (Table III). Basic fibroblast growth factor receptor 1 (Fgfr1) was also down-regulated. It was noteworthy that hepatocyte growth factor (Hgf), which contributes to hepatocyte proliferation and prevention of liver fibrosis, was up-regulated. Two cytokine-related proteins, interleukin-18 (Il18) and interleukin-1 receptor-like 2 (Il1rl2), were also up-regulated (Table III).

Using Western blot analysis, we confirmed changes in the expression of several proteins. Marked down-regulation of α -SMA and TGF- β 1 was observed with IFN- γ treatment, whereas PDGFR- β 1 was slightly down-regulated. Quantitative results obtained by 2-DE and Western blotting were not always precisely matched.

Among extracellular matrix components, the expression of three proteins associated with hyaluronic acid synthesis was down-regulated upon treatment with IFN- γ (Table III). Unfortunately, we were unable to examine exocrine proteins (e.g., collagen content) in the culture supernatant, because the action of IFN- γ on HSCs requires a small amount of FBS (0.3%), and this would have interfered with accurate 2-DE analysis of the supernatant contents.

Five proteases were down-regulated by IFN- γ treatment. It is well known that suppression of plasminogen activator (Plat) and matrix metalloproteinase-9 (Mmp9) contributes to




Figure 3. Western blot analysis of a structural molecule (α -SMA), fibrosis-implementing factors (PDGFR- β 1 and TGF- β 1), ADAM17, and pro-TNF- α (26 kDa) after IFN- γ treatment for 48 h. Marked down-regulation of α -SMA, TGF- β 1 and ADAM17 was observed, and a slight decrease was seen in PDGFR- β 1. No change in pro-TNF- α expression was evident.




Figure 4. MALDI-TOF MS fingerprint pattern for a spot of interest (No. 3 in Fig. 1A) digested with trypsin. Fingerprint mass spectra were generated via MALDI-TOF MS analysis. The predicted peptide fragments corresponding to the observed m/z values indicated ADAM17.

repression of fibrosis not only in skin wounds but also the liver. Interestingly, two members of the ADAM family were down-regulated. ADAM2 is associated with spermatogenesis. ADAM17 (no. 3 in Fig. 1A and Fig. 4) plays a pivotal role in the cleavage of membrane-associated cytokines (e.g., TNF- α) and receptors (e.g., TNF receptor) and thereby regulates inflammatory and immune events, as well as embryo development. We examined the expression of ADAM17 and TNF- α under the influence of IFN- γ , and this is described in a later section below.

Four enzymes of long-chain fatty acid synthesis were up-regulated with IFN- γ treatment. Hepatocytes take up retinol

Table III. Summary of genes of interest associated with phenotypes of activated HSCs.

| | Well described genes | | | | | Not described genes | | | | |
|--|----------------------|-------------|-------------|---|----|---------------------|-------------|-------------|---|----|
| | No. | Fold change | Gene symbol | Status of mRNA/ protein expression HSC MFLC/AF | | No. | Fold change | Gene symbol | Status of mRNA/ protein expression HSC MFLC/AF | |
| Down-regulation | | | | | | | | | | |
| Extracellular matrix | 37 | -3.0 | Has2 | NE | I | 8 | -3.9 | Hapln2 | NE | NE |
| | | | | | | 13 | -3.1 | Hmmr | NE | NE |
| Protease/protease inhibitor | 16 | -13.2 | Plat | I | I | 3 | -7.4 | Adam17 | NE | I |
| | 44 | -3.3 | Ece1 | I | I | 6 | -3.9 | Adam2 | NE | NE |
| | 35 | -3.1 | Mmp9 | I | I | | | | | |
| Cytokine, growth factors and their receptors | 39 | -6.0 | Fgfr1 | NE | I | | | | | |
| | 40 | -5.5 | Pdgfrb | I | I | | | | | |
| | 41 | -4.1 | Tgfbr1 | I | I | | | | | |
| | 45 | -3.0 | Tgfb1 | I | I | | | | | |
| Structural molecule | 47 | -7.1 | Vim | I | I | 46 | -9.9 | Add2 | I | NE |
| | 49 | -3.3 | Acta2 | I | I | 48 | -4.2 | Tubb | NE | NE |
| | 50 | -3.0 | Gfap | I | I | | | | | |
| Up-regulation | | | | | | | | | | |
| Cytokine, growth factors and their receptors | 122 | 3.1 | Hgf | I | NE | 62 | 5.9 | Il1rl2 | NE | NE |
| | | | | | | 121 | 3.3 | Il18 | NE | NE |
| Structural molecule | 123 | 3.9 | Des | I | I | | | | | |
| Fatty acid metabolism | | | | | | 102 | 3.4 | Acsl3 | NE | NE |
| | | | | | | 120 | 3.4 | Ppara | NE | NE |
| | | | | | | 104 | 3.3 | Acsl4 | NE | NE |
| | | | | | | 112 | 3.1 | Slc27a2 | NE | NE |
| | | | | | | 114 | 3.0 | Acsl6 | NE | NE |

No., number (numbers are identical to those in Fig. 1); HSC, hepatic stellate cell; MFLC, myofibroblast-like cell; AF, activated fibroblast; I, increase; NE, not evaluated. Gene symbols: Acsl3, long-chain-fatty-acid-CoA ligase 3; Acsl4, long-chain-fatty-acid-CoA ligase 4; Acsl6, long-chain-fatty-acid-CoA ligase 6; Acta2, aortic smooth muscle; Adam17, a disintegrin and metalloproteinase domain 17 (tumor necrosis factor α , converting enzyme); Adam2, a disintegrin and metalloproteinase domain 2; Add2, β adducin; Des, desmin; Ece1, endothelin-converting enzyme 1; Fgfr1, basic fibroblast growth factor receptor 1; Gfap, glial fibrillary acidic protein, astrocyte; Hapln2, hyaluronan and proteoglycan link protein 2; Has2, hyaluronan synthase 2; Hgf, hepatocyte growth factor; Hmmr, hyaluronan mediated motility receptor; Il18, interleukin-18; Il1rl2, interleukin-1 receptor-like 2; Ilf3, interleukin enhancer-binding factor 3; Mmp9, matrix metalloproteinase-9; Pdgfrb, β platelet-derived growth factor receptor; Plat, tissue-type plasminogen activator; Ppara, peroxisome proliferator activated receptor α ; Slc27a2, very-long-chain acyl-CoA synthetase; Tgfb1, transforming growth factor β 1; Tgfb1, TGF- β receptor type I; Tubb, tubulin β chain; Vim, vimentin.

esters from chylomicron remnants, and after hydrolysis the retinol is transferred to HSCs and subsequently stored as esters of long-chain fatty acids. After administration of long-chain fatty acids or retinol, retinol ester droplets are formed. Thus, an increase of cytoplasmic long-chain fatty acids may contribute to the formation of retinol-rich droplets in HSCs.

mRNA/protein expression of ADAM17 and TNF- α in HSCs after IFN- γ treatment and concentration of TNF- α in culture

supernatant. First, using quantitative PCR, we examined the expression of ADAM17 and TNF- α mRNAs after IFN- γ treatment for 6 h (Table IV, Fig. 5). IFN- γ treatment induced down-regulation of ADAM17 mRNA expression (Fig. 5A) but not that of TNF- α mRNA (Fig. 5B). Western blotting confirmed the decrease of ADAM17 protein expression after IFN- γ treatment for 48 h (Fig. 3), but that of pro-TNF- α (26 kDa) was not altered (the signals being relatively weak both before and after treatment). These results suggested that




Figure 5. Amplification plots for ADAM17 (A) and TNF- α (B). mRNAs extracted from HSCs with (b and d) and without (a and c) IFN- γ treatment. Decreased expression of ADAM17 mRNA (a and b) but not TNF- α mRNA (c and d) was observed after IFN- γ treatment.




Figure 6. Concentrations of TNF- α in supernatant of HSC cultures with and without IFN- γ treatment for 6, 12 and 48 h. A marked decrease of TNF- α was observed, irrespective of duration.

Table IV. Results of real-time quantitative PCR for TNF- α and ADAM17 expression after IFN- γ treatment for 6 h using a comparative Ct method ($\Delta\Delta C_t$ ratio).

| Subjects | $\Delta\Delta C_t$ ratio of targets (with/without IFN- γ treatment) | | |
|---------------|---|-------|--------|
| | Mean | SD | CV (%) |
| TNF- α | 1.025 | 0.380 | 5.0 |
| ADAM17 | 0.586 | 0.270 | 4.3 |

SD, standard deviation; CV, coefficient of variation.

IFN- γ treatment affected the expression of ADAM17 but not that of TNF- α . We next examined the concentration of TNF- α in the culture supernatant using a Suspension Array System. The concentration of TNF- α was almost constant for 6, 12, and 48 h in the non-treatment control, but markedly down-regulated by IFN- γ treatment for any duration (Fig. 6).

Discussion

Several cytokines regulating the inflammatory response to injury modulate hepatic fibrogenesis *in vivo* and *in vitro* (28). Among them, TNF- α plays a pivotal role in stimulating HSC activation regardless of the inflammatory etiology. It is well known that hepatocytes, Kupffer cells, sinusoidal endothelial cells and inflammatory cells secrete TNF- α , while HSCs themselves have not been considered a TNF- α -producing cell type (29). Our results of quantitative PCR and Western blot analysis suggested that IFN- γ treatment of cultured HSCs decreased TNF- α secretion through down-regulation of ADAM17 expression, rather than down-regulation of TNF- α expression itself. The autocrine action of TNF- α might partly contribute to the mechanism of activation of cultured HSCs, and down-regulation of ADAM17 by IFN- γ treatment might block its auto-activation mechanism.

IFN- γ belongs to the type II interferon family, and selectively binds to the type II IFN receptor (consisting of two distinct subunits, IFNGR1 and IFNGR2) followed by activation of the JAK-STAT signaling pathway (30). Transcription of type II IFN-dependent genes is regulated by GAS (IFN- γ -activated site) elements, and STAT1 is the most important IFN- γ -activated factor for the regulation of these transcriptional responses (30). However, in a database search, we failed to find any GAS element in the promoter region of the rat ADAM17 gene. Therefore, repression of ADAM17 mRNA/protein expression may occur through an indirect response to IFN- γ -JAK-STAT signaling.

ADAM17 has been identified as the main secretase responsible for releasing the soluble form of TNF- α from the plasma membrane (31,32). Recent studies have demonstrated that ADAM17 plays a pivotal role in development through the processing of numerous growth factors and their receptors, such as TGF- α (33), heparin-binding epidermal growth factor-like growth factor (HB-EGF) (34), amphiregulin (34), neuregulins (35), TrkA (36), growth hormone receptors (37), and others. A recent *in vitro* study showed that ADAM17-dependent shedding of TGF- α and HB-EGF was stimulated by angiotensin II (AngII), and transactivated EGFR (38). Lautrette *et al* (39) demonstrated that model mice with chronic renal disease induced by AngII infusion could be rescued by

transfection of dominant negative form of epidermal growth factor receptor (EGFR) as well as by administration of ADAM17 inhibitor. These reports suggest that ADAM17 inhibitors may prevent cell proliferation and matrix deposition by evading the AngII-EGFR pathway, and are suitable as therapeutic agents for chronic renal and cardiovascular diseases characterized by marked fibrosis (38,39).

AngII also seems to play a pivotal role in liver fibrosis. Activated HSCs produce AngII *in vitro* and *in vivo* (40,41). AngII induces hepatic inflammation and stimulates an array of fibrogenic actions in activated HSCs, including cell proliferation, cell migration, secretion of proinflammatory cytokines, and collagen synthesis (42-44). Moreover, pharmacologic and/or genetic ablation of the renin-angiotensin system markedly attenuates experimental liver fibrosis (45-51). The same mechanism (AngII-ADAM17-TGF- α /HB-EGF-EGFR) may exist in activated HSCs, and IFN- γ represses the pathway through down-regulation of ADAM17 expression.

ADAM17 also cleaves several cytokines and their receptors, such as soluble TNF- α , TNF- α receptors (33), interleukin (IL)-1-RII (52), and IL-6-R α (53). These factors contribute to accelerating the activation of HSCs. In fact, we have confirmed that the concentrations of IL-1 and IL-6 are decreased in the supernatant of cultured HSCs after IFN- γ treatment (data not shown). IFN- γ may induce changes in activated HSCs toward a quiescent phenotype through down-regulation of multiple cytokines and their receptors.

Our proteomic analysis indicated that several factors were associated with the HSC phenotypic transformation response to IFN- γ treatment. Although the relationship of both the TGF- β 1 and PDGF signaling pathways to HSC activation has been well described, few studies have focused on the function of HSCs as fat-storing cells. We demonstrated up-regulation of enzymes involved in long-chain fatty acid synthesis, and this is an aspect that will warrant further examination. Quiescent HSCs express markers that are characteristic of adipocytes (e.g., PPARs), and the expression of these markers is increased in activated HSCs (54). A few reports have noted that IFN- γ down-regulates PPAR γ mRNA/protein expression through STAT signaling in adipocytes (55). Further studies will be required to clarify the mechanisms involved in the phenotypic change of activated HSCs to fat-storing cells.

In this study we have demonstrated that several pathways responding to IFN- γ treatment appear to induce changes in activated HSCs toward a quiescent phenotype. A recent clinical trial of IFN- γ administration has demonstrated an effective antifibrogenic action in patients with chronic hepatitis B virus infection (56). It is anticipated that combination therapy with IFN- γ and other drugs (e.g., AngII antagonist or ADAM17 inhibitors) will be developed for the treatment and prevention of liver fibrosis.

References

- Milani S, Herbst H, Schuppan D, Hahn EG and Stein H: *In situ* hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. *Hepatology* 10: 84-92, 1989.
- Friedman SL: Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. *N Engl J Med* 328: 1828-1835, 1993.
- Yokoi Y, Namihisa T, Kuroda H, *et al*: Immunocytochemical detection of desmin in fat-storing cells (Ito cells). *Hepatology* 4: 709-714, 1984.
- Pinzani M, Gesualdo L, Sabbah GM and Abboud HE: Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. *J Clin Invest* 84: 1786-1793, 1989.
- Ramadori G, Veit T, Schwogler S, *et al*: Expression of the gene of the alpha-smooth muscle-actin isoform in rat liver and in rat fat-storing (ITO) cells. *Virchows Arch B Cell Pathol Incl Mol Pathol* 59: 349-357, 1990.
- Hendriks HF, Verhoofstad WA, Brouwer A, De Leeuw AM and Knook DL: Perisinusoidal fat-storing cells are the main vitamin A storage sites in rat liver. *Exp Cell Res* 160: 138-149, 1985.
- Blomhoff R and Wake K: Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. *FASEB J* 5: 271-277, 1991.
- Friedman SL, Rockey DC, McGuire RF, Maher JJ, Boyles JK and Yamasaki G: Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. *Hepatology* 15: 234-243, 1992.
- Rockey DC, Boyles JK, Gabbiani G and Friedman SL: Rat hepatic lipocytes express smooth muscle actin upon activation *in vivo* and in culture. *J Submicrosc Cytol Pathol* 24: 193-203, 1992.
- Burt AD, Le Bail B, Balabaud C and Bioulac-Sage P: Morphologic investigation of sinusoidal cells. *Semin Liver Dis* 13: 21-38, 1993.
- Seyer JM, Hutcheson ET and Kang AH: Collagen polymorphism in normal and cirrhotic human liver. *J Clin Invest* 59: 241-248, 1977.
- Kent G, Gay S, Inouye T, Bahu R, Minick OT and Popper H: Vitamin A-containing lipocytes and formation of type III collagen in liver injury. *Proc Natl Acad Sci USA* 73: 3719-3722, 1976.
- Scharffetter K, Heckmann M, Hatamochi A, *et al*: Synergistic effect of tumor necrosis factor-alpha and interferon-gamma on collagen synthesis of human skin fibroblasts *in vitro*. *Exp Cell Res* 181: 409-419, 1989.
- Jimenez SA, Freundlich B and Rosenbloom J: Selective inhibition of human diploid fibroblast collagen synthesis by interferons. *J Clin Invest* 74: 1112-1116, 1984.
- Rosenbloom J, Feldman G, Freundlich B and Jimenez SA: Transcriptional control of human diploid fibroblast collagen synthesis by gamma-interferon. *Biochem Biophys Res Commun* 123: 365-372, 1984.
- Duncan MR and Berman B: Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. *J Exp Med* 162: 516-527, 1985.
- Goldring MB, Sandell LJ, Stephenson ML and Krane SM: Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes. *J Biol Chem* 261: 9049-9055, 1986.
- Smith DD, Gowen M and Mundy GR: Effects of interferon-gamma and other cytokines on collagen synthesis in fetal rat bone cultures. *Endocrinology* 120: 2494-2499, 1987.
- Tsuruoka N, Sugiyama M, Tawaragi Y, *et al*: Inhibition of *in vitro* angiogenesis by lymphotoxin and interferon-gamma. *Biochem Biophys Res Commun* 155: 429-435, 1988.
- Granstein RD, Deak MR, Jacques SL, *et al*: The systemic administration of gamma interferon inhibits collagen synthesis and acute inflammation in a murine skin wounding model. *J Invest Dermatol* 93: 18-27, 1989.
- Shen H, Zhang M, Minuk GY and Gong Y: Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation. *BMC Cell Biol* 3: 9, 2002.
- Vaillant B, Chiamonte MG, Cheever AW, Soloway PD and Wynn TA: Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. *J Immunol* 167: 7017-7026, 2001.
- Senoo H: Structure and function of hepatic stellate cells. *Med Electron Microsc* 37: 3-15, 2004.
- Rockey DC, Maher JJ, Jarnagin WR, Gabbiani G and Friedman SL: Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. *Hepatology* 16: 776-784, 1992.
- Rosenfeld J, Capdevielle J, Guillemot JC and Ferrara P: In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. *Anal Biochem* 203: 173-179, 1992.

26. Katayama H, Nagasu T and Oda Y: Improvement of in-gel digestion protocol for peptide mass fingerprinting by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom* 15: 1416-1421, 2001.
27. Aarskog NK and Vedeler CA: Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. *Hum Genet* 107: 494-498, 2000.
28. Marra F: Chemokines in liver inflammation and fibrosis. *Front Biosci* 7: 1899-1914, 2002.
29. Bataller R and Brenner DA: Liver fibrosis. *J Clin Invest* 115: 209-218, 2005.
30. Plataniias LC: Mechanisms of type-I- and type-II-interferon-mediated signalling. *Nat Rev Immunol* 5: 375-386, 2005.
31. Black RA, Rauch CT, Kozlosky CJ, *et al*: A metalloproteinase disintegrin that releases tumour-necrosis factor- α from cells. *Nature* 385: 729-733, 1997.
32. Moss ML, Jin SL, Milla ME, *et al*: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor- α . *Nature* 385: 733-736, 1997.
33. Peschon JJ, Slack JL, Reddy P, *et al*: An essential role for ectodomain shedding in mammalian development. *Science* 282: 1281-1284, 1998.
34. Sunnarborg SW, Hinkle CL, Stevenson M, *et al*: Tumor necrosis factor- α converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. *J Biol Chem* 277: 12838-12845, 2002.
35. Montero JC, Yuste L, Diaz-Rodriguez E, Esparis-Ogando A and Pandiella A: Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor- α -converting enzyme. *Mol Cell Neurosci* 16: 631-648, 2000.
36. Diaz-Rodriguez E, Montero JC, Esparis-Ogando A, Yuste L and Pandiella A: Extracellular signal-regulated kinase phosphorylates tumor necrosis factor α -converting enzyme at threonine 735: a potential role in regulated shedding. *Mol Biol Cell* 13: 2031-2044, 2002.
37. Zhang Y, Jiang J, Black RA, Baumann G and Frank SJ: Tumor necrosis factor- α converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. *Endocrinology* 141: 4342-4348, 2000.
38. Mifune M, Ohtsu H, Suzuki H, *et al*: G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-I receptor. *J Biol Chem* 280: 26592-26599, 2005.
39. Lautrette A, Li S, Alili R, *et al*: Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. *Nat Med* 11: 867-874, 2005.
40. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM and Angus PW: Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. *Gastroenterology* 123: 1667-1676, 2002.
41. Bataller R, Sancho-Bru P, Gines P, *et al*: Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. *Gastroenterology* 125: 117-125, 2003.
42. Bataller R, Schwabe RF, Choi YH, *et al*: NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. *J Clin Invest* 112: 1383-1394, 2003.
43. Bataller R, Gines P, Nicolas JM, *et al*: Angiotensin II induces contraction and proliferation of human hepatic stellate cells. *Gastroenterology* 118: 1149-1156, 2000.
44. Bataller R, Gabele E, Schoonhoven R, *et al*: Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. *Am J Physiol Gastrointest Liver Physiol* 285: G642-G651, 2003.
45. Kanno K, Tazuma S and Chayama K: AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl₄. *Biochem Biophys Res Commun* 308: 177-183, 2003.
46. Jonsson JR, Clouston AD, Ando Y, *et al*: Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. *Gastroenterology* 121: 148-155, 2001.
47. Paizis G, Gilbert RE, Cooper ME, *et al*: Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. *J Hepatol* 35: 376-385, 2001.
48. Ramalho LN, Ramalho FS, Zucoloto S, *et al*: Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. *Hepatogastroenterology* 49: 1499-1502, 2002.
49. Wei HS, Lu HM, Li DG, *et al*: The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl₄. *World J Gastroenterol* 6: 824-828, 2000.
50. Wei HS, Li DG, Lu HM, *et al*: Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl₄. *World J Gastroenterol* 6: 540-545, 2000.
51. Tuncer I, Ozbek H, Ugras S and Bayram I: Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. *Exp Toxicol Pathol* 55: 159-166, 2003.
52. Reddy P, Slack JL, Davis R, *et al*: Functional analysis of the domain structure of tumor necrosis factor- α converting enzyme. *J Biol Chem* 275: 14608-14614, 2000.
53. Althoff K, Reddy P, Voltz N, Rose-John S and Mullberg J: Shedding of interleukin-6 receptor and tumor necrosis factor α . Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. *Eur J Biochem* 267: 2624-2631, 2000.
54. Hellemans K, Michalik L, Dittie A, *et al*: Peroxisome proliferator-activated receptor- β signaling contributes to enhanced proliferation of hepatic stellate cells. *Gastroenterology* 124: 184-201, 2003.
55. Waite KJ, Floyd ZE, Arbour-Reilly P and Stephens JM: Interferon- γ -induced regulation of peroxisome proliferator-activated receptor γ and STATs in adipocytes. *J Biol Chem* 276: 7062-7068, 2001.
56. Weng HL, Wang BE, Jia JD, *et al*: Effect of interferon- γ on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. *Clin Gastroenterol Hepatol* 3: 819-828, 2005.